Resumen de Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer

E. Nadal, Martín Oré Arce, Jordi Remón Masip, Reyes Bernabé-Caro, Marta Covela Rúa, Javier de Castro Carpeño, Bartomeu Massuti Sureda, Mónica Maria Guillot Morales, Margarita Majem, Inmaculada Maestu Maiques, Idoia Morilla, Regina Gironés Sarrió

• Lung cancer (LC) is associated with ageing, with the average age of affected individuals being approximately 70 years. However, despite a higher incidence and prevalence among older people, the older adult population is underrepresented in clinical trials. For LC with Epidermal Growth Factor Receptor (EGFR) mutations, there is no clear association of this mutation with age. Geriatric assessments (GAs) and a multidisciplinary approach are essential for defining the optimal treatment. In this consensus, a group of experts selected from the Oncogeriatrics Section of the Spanish Society of Medical Oncology (Sección de Oncogeriatría de la Sociedad Española de Oncología Médica—SEOM), the Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón—GECP) and the Association for Research on Lung Cancer in Women (Asociación para la Investigación del Cáncer de Pulmón en Mujeres—ICAPEM) evaluate the scientific evidence currently available and propose a series of recommendations to optimize the management of older adult patients with advanced LC with EGFR mutations.